Overview

PEARL Schizophrenia Maintenance

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

Lurasidone HCI is a compound that is FDA-approved for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that Lurasidone is effective in the long term maintenance treatment of schizophrenia.

Phase:

Phase 3

Details

Lead Sponsor:

Sunovion

Treatments:

Lurasidone Hydrochloride